AACR24: Robert Haddad, MD, Head and Neck | Dana-Farber Cancer Institute [Video]

Head and Neck Cancer Research at AACR24: Important IMvoke010 trial could shape future research in immunotherapy in locally advanced head & neck cancer after results of 1st phase III study in adjuvant therapy don’t meet event-free survival endpoint. Dana-Farber’s Robert Haddad, MD, explains more in this video.
Video published 4/10/2024